Lodie Naimeh in Tulsa, Oklahoma

Medical School: Sorry, her university is not listed
Graduation Year: 1989
The Primary Medical Specialty for Lodie Naimeh is listed as: Allergy/immunology
Approximate Years of Experience: 36
PAC (PECOS ID)#: 0840326070
NPI #: 1265413462
NPI Created On: 11/07/2005
NPI Last Updated Listed as: 11/02/2012
Primary Taxonomy Code: 207KA0200X
License Number:
21695
Listed Gender: Female

Forms of insurance accepted by include, but are not limited to:

• Humana
• Blue Cross Blue Shield
• CommunityCare HMO Inc.
• Medicare

They are listed as accepting new patients.

Languages spoken by staff include: English, Lebanese, French, Aramaic, Spanish, FRENCH, ENGLISH.

Services and Procedures include:

1. Vaccine for influenza for injection into muscle
2. Measurement and graphic recording of the amount and speed of breathed air, before and following medication administration
3. Injection of allergenic extracts into skin, accessed through the skin
4. Injection of allergenic extracts into skin for immediate reaction analysis
5. Injection of incremental dosages of allergen
6. Injection of incremental dosages of allergen, 2 or more injections
7. Preparation and provision of single or multiple antigens for allergen immunotherapy
8. Infusion into a vein for therapy, prevention, or diagnosis up to 1 hour
9. Infusion into a vein for therapy, prevention, or diagnosis
10. Infusion into tissue for therapy or prevention up to 1 hour
11. Infusion into tissue for therapy or prevention, beneath the skin
12. Non-hormonal anti-neoplastic chemotherapy beneath the skin or into muscle
13. New patient office or other outpatient visit, typically 45 minutes
14. Established patient office or other outpatient visit, typically 15 minutes
15. Established patient office or other outpatient, visit typically 25 minutes
16. Administration of influenza virus vaccine
17. Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg
18. Injection, immune globulin/hyaluronidase, (hyqvia), 100 mg immuneglobulin
19. Injection, omalizumab, 5 mg
20. Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg